Eocene Ltd.

GLMDNasdaqCM

$4.63▲ +0.81 (+21.05%)

Market openData as of 01:10 PM ET · 15-min delay

Analyst ratingnone

Every calculator, already run for GLMD

What is it worth?

P/E calculatorHow does this multiple compare to peers and its own history?Run →DCF calculatorTen years of free cash flow, discounted back to today.Run →Reverse DCFSolves the price backwards for the growth it already requires.Run →EV / EBITDAThe price with debt added and cash netted off.Run →PEG ratioThe multiple divided by the growth meant to justify it.Run →Graham numberGraham's ceiling from earnings and book value.Run →P/S ratioFor companies whose earnings are not the point yet.Run →Intrinsic valueDCF, multiples and Graham run together as one range.Run →

Is it any good?

ROIC calculatorWhether a dollar invested earns more than it costs.-57.0%Altman Z-scoreFive balance-sheet ratios weighted into a distress score.-15.29 · distress Piotroski F-scoreNine pass-fail tests on profit, leverage and efficiency.1 of 6 Debt to equityHow much of the balance sheet is borrowed.0.00 Interest coverageHow many times operating profit covers the interest bill.Run →Profit marginGross, operating and net, each against the sector.0.0% net Free cash flowOperating cash after the capex needed to keep going.-$5M Rule of 40Revenue growth plus margin, the software health line.

What does it return & pay?

ROE calculatorProfit against the equity shareholders left in.-68.2%EPS growthEarnings per share compounded over the filings.Run →CAGR calculatorCompound rate on revenue, earnings, cash or price.Run →Dividend yieldWhat it pays, and whether free cash flow covers it.0.00%Net payout yieldDividends plus buybacks, less shares issued.Run →Owner earningsBuffett's version: cash a buyer could actually take out.-$5M

You have the numbers on GLMD. Get the argument.

A written report on which of these readings actually decide the outcome for Eocene Ltd., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.

Key market data

Market cap$4.95M

P/E (TTM)—

Forward P/E-4.5x

Beta0.67

EPS (TTM)$-14.29

Dividend yield—

Volume301.2K

Avg volume43.2K

52-week range

$3.27$4.88

Analyst consensus

1 analysts covering GLMD

Buy0

Hold1

Sell0

Ownership & short interest

Institutions1.9%

Insiders3.0%

Shares out$1.07M

Insider Trading Activity for GLMD

Insider	Role	Type	Shares	Price	Value	Date	Filing

About Eocene Ltd.

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methi…

3 employeesIsrael

GLMD — frequently asked

Is GLMD a buy right now?

Wall Street's consensus rating on Eocene Ltd. is none across 1 analysts. Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.

Compare Eocene Ltd. against related stocks

Explore additional stock overview pages and jump directly into full report generation for each symbol.

Nearby tickers

Additional public equities from our tracked universe.

GLEO stock overview GLDD stock overview GLNG stock overview GLBE stock overview GLPG stock overview GL stock overview GLW stock overview

Market leaders

Large-cap symbols investors frequently compare.

AAPL stock overview MSFT stock overview NVDA stock overview AMZN stock overview GOOGL stock overview META stock overview TSLA stock overview JPM stock overview

Investor Guides For Eocene Ltd.

Start with the evergreen guides that matter most for this sector, then move back into the ticker page when you want to pressure-test the framework on a live name.

Investor FoundationsStock valuation: frame the implied case before the model Investor FoundationsDCF: model the economics before the spreadsheet does Investor FoundationsDCF sensitivity: make the fragile assumptions visible Investor FoundationsStock multiples: read the argument inside the number

Generate your full GLMD research report

DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Eocene Ltd., in minutes. 3 free reports included with every account — no credit card required.